282 related articles for article (PubMed ID: 12218569)
41. Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
Maria S; Faron M; Maulard A; Pautier P; Leary A; Chargari C; Genestie C; Gouy S; Morice P
Gynecol Oncol; 2020 Sep; 158(3):659-665. PubMed ID: 32571680
[TBL] [Abstract][Full Text] [Related]
42. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
43. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases.
Gilks CB; Alkushi A; Yue JJ; Lanvin D; Ehlen TG; Miller DM
Int J Gynecol Pathol; 2003 Jan; 22(1):29-36. PubMed ID: 12496695
[TBL] [Abstract][Full Text] [Related]
44. Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study.
Fauvet R; Demblocque E; Morice P; Querleu D; Daraï E
Ann Surg Oncol; 2012 Mar; 19(3):941-7. PubMed ID: 21879267
[TBL] [Abstract][Full Text] [Related]
45. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract][Full Text] [Related]
46. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
[TBL] [Abstract][Full Text] [Related]
47. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
[TBL] [Abstract][Full Text] [Related]
48. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
[TBL] [Abstract][Full Text] [Related]
49. High-grade ovarian serous carcinomas: Significant correlation of histologic patterns with IMP3 and E-Cadherin predicting disease recurrence and survival.
Mohanty SK; Tiwari A; Singh C; Walsh C; Chuang F; Kim E; Singh K; Dadmanesh F
Ann Diagn Pathol; 2019 Jun; 40():30-39. PubMed ID: 30921622
[TBL] [Abstract][Full Text] [Related]
50. Micropapillary pattern in serous borderline ovarian tumors: does it matter?
Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2011 Dec; 123(3):511-6. PubMed ID: 21917305
[TBL] [Abstract][Full Text] [Related]
51. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
Vereczkey I; Tóth E; Orosz Z
Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
[TBL] [Abstract][Full Text] [Related]
52. Outcome of patients with advanced-stage borderline ovarian tumors after a first peritoneal noninvasive recurrence: impact on further management.
Uzan C; Zanini-Grandon AS; Bentivegna E; Gouy S; Leary A; Duvillard P; Morice P
Int J Gynecol Cancer; 2015 Jun; 25(5):830-6. PubMed ID: 25828751
[TBL] [Abstract][Full Text] [Related]
53. Grade 1 peritoneal serous carcinomas: a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors.
Weir MM; Bell DA; Young RH
Am J Surg Pathol; 1998 Jul; 22(7):849-62. PubMed ID: 9669347
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
55. Bilateral micropapillary serous carcinoma of the ovary: a case report.
Gupta R; Singh S; Nigam S
Arch Gynecol Obstet; 2007 May; 275(5):401-4. PubMed ID: 17031658
[TBL] [Abstract][Full Text] [Related]
56. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
57. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
58. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases.
Bostwick DG; Tazelaar HD; Ballon SC; Hendrickson MR; Kempson RL
Cancer; 1986 Nov; 58(9):2052-65. PubMed ID: 3756820
[TBL] [Abstract][Full Text] [Related]
59. The Factors Predicting Recurrence in Patients With Serous Borderline Ovarian Tumor.
Ureyen I; Karalok A; Tasci T; Turkmen O; Boran N; Tulunay G; Turan T
Int J Gynecol Cancer; 2016 Jan; 26(1):66-72. PubMed ID: 26512785
[TBL] [Abstract][Full Text] [Related]
60. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
